Anmelden Kostenlos registrieren

Starpharma Beta

Was ist das Beta von Starpharma?

Beta von Starpharma Holdings Limited ist 1.12

Was ist die Definition von Beta?



BETA gibt an, ob eine Aktie mehr oder weniger schwankungsanfällig ist als der Gesamtmarkt. Ein Beta von weniger als 1 zeigt an, dass die Aktie weniger schwankungsanfällig ist als der Markt, während ein Beta von mehr als 1 anzeigt, dass die Aktie mehr schwankungsanfällig ist. Die Schwankungsanfälligkeit wird als Schwankung des Preises um den Mittelwert gemessen.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.

Beta von Unternehmen in Health Care Sektor auf ASX im Vergleich zu Starpharma

Was macht Starpharma?

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Unternehmen mit beta ähnlich Starpharma